| Solid Neoplasm
Augtyro vs Jemperli
Side-by-side clinical, coverage, and cost comparison for solid neoplasm.Deep comparison between: Augtyro vs Jemperli with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsJemperli has a higher rate of injection site reactions vs Augtyro based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Jemperli but not Augtyro, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Augtyro
Jemperli
At A Glance
Oral
Once daily x14 days, then twice daily
ROS1/TRK inhibitor
IV infusion
Every 3-6 weeks
PD-1 inhibitor
Indications
- Non-Small Cell Lung Carcinoma
- Solid Neoplasm
- Endometrial Carcinoma
- Solid Neoplasm
Dosing
Non-Small Cell Lung Carcinoma, Solid Neoplasm 160 mg orally once daily for 14 days, then increase to 160 mg twice daily, with or without food, until disease progression or unacceptable toxicity.
Endometrial Carcinoma 500 mg IV every 3 weeks for 6 cycles with carboplatin and paclitaxel, followed by 1,000 mg IV monotherapy every 6 weeks; administer prior to carboplatin and paclitaxel when given on the same day.
Endometrial Carcinoma, Solid Neoplasm 500 mg IV every 3 weeks for 4 cycles followed by 1,000 mg IV every 6 weeks as monotherapy; for dMMR-selected patients only.
Contraindications
—
—
Adverse Reactions
Most common (>=20%) Dizziness, dysgeusia, peripheral neuropathy, constipation, dyspnea, fatigue, ataxia, cognitive impairment, muscular weakness, nausea.
Serious Pneumonia, dyspnea, pleural effusion, hypoxia.
Most common (>=20%) Fatigue, nausea, diarrhea, constipation, vomiting, anemia, peripheral neuropathy, alopecia, rash, arthralgia, abdominal pain, dyspnea, decreased appetite, urinary tract infection
Serious Sepsis (including urosepsis), pulmonary embolism, urinary tract infection, acute kidney injury, abdominal pain
Pharmacology
Repotrectinib is a kinase inhibitor of ROS1 and tropomyosin receptor tyrosine kinases (TRKA, TRKB, TRKC); fusion proteins containing these domains drive tumorigenic potential through hyperactivation of downstream signaling pathways leading to unconstrained cell proliferation.
Dostarlimab-gxly is a humanized IgG4 monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Augtyro
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
Jemperli
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Augtyro
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (6/8)
Jemperli
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Augtyro
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Jemperli
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Augtyro.
No savings programs available for Jemperli.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AugtyroView full Augtyro profile
JemperliView full Jemperli profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.